| Date |
Acquiring pharma company |
Acquired biotech company |
Amount |
Terms / other |
| 2008-07-25 |
Sanofi-Aventis (France) |
Acambis (UK) |
£276 million (€350 million) |
See details |
| 2008-07-23 |
Roche (Switzerland) |
Arius Research (Canada) |
CAN$ 191 millions (€ 122 million) |
See details |
| 2008-07-22 |
Roche (Switzerland) |
Mirus Bio Corporation (USA) |
$ 125 million (€ 84.5 million) |
See details |
| 2008-07-10 |
Novartis (Switzerland) |
Speedel (Switzerland) |
CHF 907 million ($ 880 million) |
See details |
| 2008-07-03 |
Shire (GB) |
Jerini (Germany) |
€328 million |
See details |
| 2008-06-17 |
Boehringer Ingelheim (Germany) |
Actimis Pharmaceuticals (USA) |
US$ 515 million. |
See details |
| 2008-06-09 |
Sygnis Pharma (Germany) |
Amnestix (USA) |
€4 million in cash and shares |
See details |
| 2008-06-05 |
Ipsen (France) |
Tercica (USA) |
$ 404 million (€ 262.5 million) |
See details |
| 2008-06-05 |
Ipsen (France) |
Vernalis Pharmaceuticals (USA - US subsidiary of Vernalis-UK) |
$12.5 million (€8.1 million1). |
See details |
| 2008-06-04 |
Novartis (Switzerland) |
Protez Pharmaceuticals (USA) |
$100 million
|
See details |
| 2008-05-27 |
Lonza (Switzerland) |
Amaxa (Germany, USA) |
Financial details were not disclosed. |
See details |
| 2008-05-21 |
Daiichi Sankyo (Japan) |
U3 Pharma AG (Germany) |
€ 150 million ($ 235 million) |
See details |
| 2008-05-16 |
Antisoma (GB) |
Xanthus Pharmaceuticals (USA) |
GBP 26.8 million ($ 52.2 million, € 33.6 million) |
See details |
| 2008-05-12 |
Intercell (Austria) |
Iomai (USA) |
€ 122 million ($ 189 million) |
See details |
| 2008-04-15 |
Roche (Switzerland) |
Piramed (UK) |
US$ 175 million |
See details |
